One of the outpatient rehab options for individuals in Delmont who are battling with opioid dependence and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to dispense certain meds to opioid addicted people, many that are opioid-based themselves and are addictive. With low enough amounts however, the individual doesn't experience high feelings and also does not experience acute cravings and is not experiencing opioid withdrawal. Methadone is the first drug used for this reason, but there are alternative choices currently to select from.
Methadone is an opiate and can be taken at an out-patient medical center licensed to administer the drug, which is taken daily in liquid or pill form. The price of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opiate based drug, and is in pill form often taken every other day. But different from Methadone which is only be administered in highly well-regulated clinics, Buprenorphine can be prescribed and administered in doctor's offices. The monthly cost of buprenorphine is approximately $300 per month for the generic version of the medication. There is also a version of buprenorphine that contains naloxone, which is a drug that reverses the effects of opioids. Someone consuming this version of the drug, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken every day, and costs approximately $450 a month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other drugs mentioned here it's an opiate blocker and is not an opioid. A person has the choice to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Rehabilitation Programs In Delmont, Click Here.